{"id":"olaratumab","rwe":[],"tags":[{"label":"Platelet-derived Growth Factor Receptor alpha Antagonist","category":"class"},{"label":"Monoclonal Antibody","category":"modality"},{"label":"Platelet-derived growth factor receptor alpha","category":"target"},{"label":"PDGFRA","category":"gene"},{"label":"L01FX10","category":"atc"},{"label":"Active","category":"status"},{"label":"Sarcoma of soft tissue","category":"indication"},{"label":"Eli Lilly And Co","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Antineoplastic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":102.063,"date":"","count":45,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=102)"},{"llr":89.792,"date":"","count":45,"signal":"Neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=90)"},{"llr":63.259,"date":"","count":13,"signal":"Neoplasm recurrence","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=63)"},{"llr":59.839,"date":"","count":56,"signal":"Off label use","source":"DrugCentral FAERS","actionTaken":"Reported 56 times (LLR=60)"},{"llr":58.404,"date":"","count":33,"signal":"Product use in unapproved indication","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=58)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Eli Lilly","patents":[{"type":"Biologic Exclusivity","filed":"October 19, 2016","source":"FDA Purple Book","status":"Active","expires":"February 25, 2020","territory":"US","patentNumber":"BLA 761038"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=OLARATUMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:43:59.284094+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:43:59.283961+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Olaratumab","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:44:06.915121+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:44:05.239356+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:43:59.411706+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OLARATUMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:44:05.823985+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Platelet-derived growth factor receptor alpha antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:44:06.915071+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743049/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:44:06.567565+00:00"}},"allNames":"lartruvo","offLabel":[],"synonyms":["olaratumab","lartruvo","IMC-3G3","IMC3G3"],"timeline":[{"date":"2016-10-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Eli Lilly And Co)"},{"date":"2016-11-09","type":"positive","source":"DrugCentral","milestone":"EMA approval (Eli Lilly Nederland B.V.)"}],"aiSummary":"Lartruvo (Olaratumab) is a small molecule drug developed by Eli Lilly and Co, targeting the platelet-derived growth factor receptor alpha. It works as a receptor antagonist to inhibit tumor growth. Lartruvo is FDA-approved for the treatment of soft tissue sarcoma. The commercial status of Lartruvo is patented, and it is still owned by Eli Lilly and Co. Key safety considerations include potential severe side effects such as neutropenia and thrombocytopenia.","approvals":[{"date":"2016-10-19","orphan":false,"company":"ELI LILLY AND CO","regulator":"FDA"},{"date":"2016-11-09","orphan":false,"company":"Eli Lilly Nederland B.V.","regulator":"EMA"}],"brandName":"Lartruvo","ecosystem":[{"indication":"Sarcoma of soft tissue","otherDrugs":[{"name":"pazopanib","slug":"pazopanib","company":"Novartis Pharms Corp"}],"globalPrevalence":null}],"mechanism":{"target":"Platelet-derived growth factor receptor alpha","novelty":"Follow-on","targets":[{"gene":"PDGFRA","source":"DrugCentral","target":"Platelet-derived growth factor receptor alpha","protein":"Platelet-derived growth factor receptor alpha"}],"moaClass":"Platelet-derived Growth Factor alpha Receptor Inhibitors","modality":"Monoclonal Antibody","drugClass":"Platelet-derived Growth Factor Receptor alpha Antagonist","explanation":"","oneSentence":"","technicalDetail":"Lartruvo (Olaratumab) is a monoclonal antibody that binds to the platelet-derived growth factor receptor alpha (PDGFRα), inhibiting the receptor's autophosphorylation and downstream signaling pathways, which are crucial for tumor cell proliferation and survival."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Olaratumab","title":"Olaratumab","extract":"Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.","wiki_history":"== History ==\nOlaratumab was originally developed by ImClone Systems, which was acquired by Eli Lilly in 2008. A Phase I clinical trial was conducted in Japanese patients in September 2010, followed by a Phase II trial in 133 patients, starting in October 2010.\n\nIn February 2015, the European Medicines Agency assigned olaratumab orphan drug status for the treatment of soft-tissue sarcoma. The European Commission granted a conditional marketing authorisation, based on the mentioned Phase II study, valid throughout the European Union on 9 November 2016.\n\nPreviously considered a promising drug, the FDA granted olaratumab fast track designation, breakthrough therapy designation and priority review status.\nIn October 2016, the US FDA issued an accelerated approval notice for use of olaratumab with doxorubicin to treat adults with certain types of soft-tissue sarcoma, based on the same study. \n\nA phase III trial completed in 2019, and unfortunately showed no benefit from the addition of olaratumab to doxorubicin. As noted above, these results led to withdrawal of approval in the United States and Europe."},"commercial":{"launchDate":"2016","_launchSource":"DrugCentral (FDA 2016-10-19, ELI LILLY AND CO)"},"purpleBook":{"bla":"761038","source":"FDA Purple Book","approvalDate":"October 19, 2016","licenseStatus":"Voluntarily Revoked","exclusivityExpiry":"February 25, 2020"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5183","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=OLARATUMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OLARATUMAB","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Olaratumab","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://purplebooksearch.fda.gov/","fields":["biologicExclusivity"],"source":"FDA Purple Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T15:07:21.727807","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:44:09.576575+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"gemtuzumab ozogamicin","drugSlug":"gemtuzumab-ozogamicin","fdaApproval":"2000-05-17","relationship":"same-class"},{"drugName":"ipilimumab","drugSlug":"ipilimumab","fdaApproval":"2011-03-25","relationship":"same-class"},{"drugName":"brentuximab vedotin","drugSlug":"brentuximab-vedotin","fdaApproval":"2011-08-19","relationship":"same-class"},{"drugName":"blinatumomab","drugSlug":"blinatumomab","fdaApproval":"2014-12-03","relationship":"same-class"},{"drugName":"elotuzumab","drugSlug":"elotuzumab","fdaApproval":"2015-11-30","relationship":"same-class"},{"drugName":"mogamulizumab","drugSlug":"mogamulizumab","fdaApproval":"2018-08-08","relationship":"same-class"},{"drugName":"tafasitamab","drugSlug":"tafasitamab","fdaApproval":"2020-07-31","relationship":"same-class"},{"drugName":"enfortumab vedotin","drugSlug":"enfortumab-vedotin","fdaApproval":"2019-12-18","relationship":"same-class"},{"drugName":"polatuzumab vedotin","drugSlug":"polatuzumab-vedotin","fdaApproval":"2019-06-10","relationship":"same-class"},{"drugName":"belantamab mafodotin","drugSlug":"belantamab-mafodotin","fdaApproval":"2020-05-08","relationship":"same-class"},{"drugName":"sacituzumab govitecan","drugSlug":"sacituzumab-govitecan","fdaApproval":"2020-04-04","relationship":"same-class"},{"drugName":"amivantamab","drugSlug":"amivantamab","fdaApproval":"2021-05-21","relationship":"same-class"},{"drugName":"tremelimumab","drugSlug":"tremelimumab","fdaApproval":"2022-10-21","relationship":"same-class"},{"drugName":"naxitamab","drugSlug":"naxitamab","fdaApproval":"2020-11-25","relationship":"same-class"},{"drugName":"loncastuximab tesirine","drugSlug":"loncastuximab-tesirine","fdaApproval":"2021-04-23","relationship":"same-class"},{"drugName":"tisotumab vedotin","drugSlug":"tisotumab-vedotin","fdaApproval":"2021-09-20","relationship":"same-class"}],"genericName":"olaratumab","indications":{"approved":[{"name":"Sarcoma of soft tissue","source":"DrugCentral","snomedId":424952003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"gemtuzumab-ozogamicin","brandName":"gemtuzumab ozogamicin","genericName":"gemtuzumab ozogamicin","approvalYear":"2000","relationship":"same-class"},{"drugId":"ipilimumab","brandName":"ipilimumab","genericName":"ipilimumab","approvalYear":"2011","relationship":"same-class"},{"drugId":"brentuximab-vedotin","brandName":"brentuximab vedotin","genericName":"brentuximab vedotin","approvalYear":"2011","relationship":"same-class"},{"drugId":"blinatumomab","brandName":"blinatumomab","genericName":"blinatumomab","approvalYear":"2014","relationship":"same-class"},{"drugId":"elotuzumab","brandName":"elotuzumab","genericName":"elotuzumab","approvalYear":"2015","relationship":"same-class"},{"drugId":"mogamulizumab","brandName":"mogamulizumab","genericName":"mogamulizumab","approvalYear":"2018","relationship":"same-class"},{"drugId":"tafasitamab","brandName":"tafasitamab","genericName":"tafasitamab","approvalYear":"2020","relationship":"same-class"},{"drugId":"enfortumab-vedotin","brandName":"enfortumab vedotin","genericName":"enfortumab vedotin","approvalYear":"2019","relationship":"same-class"},{"drugId":"polatuzumab-vedotin","brandName":"polatuzumab vedotin","genericName":"polatuzumab vedotin","approvalYear":"2019","relationship":"same-class"},{"drugId":"belantamab-mafodotin","brandName":"belantamab mafodotin","genericName":"belantamab mafodotin","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02451943","phase":"PHASE3","title":"A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-09-14","conditions":["Soft Tissue Sarcoma"],"enrollment":509,"completionDate":"2024-06-27"},{"nctId":"NCT06537596","phase":"PHASE1","title":"89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","startDate":"2024-10-31","conditions":["Soft Tissue Sarcoma"],"enrollment":50,"completionDate":"2026-08"},{"nctId":"NCT03994627","phase":"","title":"Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma","status":"APPROVED_FOR_MARKETING","sponsor":"Eli Lilly and Company","startDate":"","conditions":["Soft Tissue Sarcoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT03126591","phase":"PHASE1","title":"A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-03","conditions":["Soft Tissue Sarcoma"],"enrollment":41,"completionDate":"2023-02-21"},{"nctId":"NCT03985722","phase":"PHASE1","title":"Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients","status":"UNKNOWN","sponsor":"Grupo Espanol de Investigacion en Sarcomas","startDate":"2018-09-21","conditions":["Sarcoma, Soft Tissue"],"enrollment":28,"completionDate":"2024-05-05"},{"nctId":"NCT03086369","phase":"PHASE1,PHASE2","title":"A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-06-22","conditions":["Metastatic Pancreatic Cancer"],"enrollment":184,"completionDate":"2021-06-17"},{"nctId":"NCT02659020","phase":"PHASE1,PHASE2","title":"A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03-01","conditions":["Soft Tissue Sarcoma"],"enrollment":310,"completionDate":"2021-04-27"},{"nctId":"NCT03056599","phase":"PHASE1","title":"Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2016-12-15","conditions":["Soft Tissue Sarcoma Adult"],"enrollment":23,"completionDate":"2021-09-22"},{"nctId":"NCT02377752","phase":"PHASE1","title":"A Study of Olaratumab in Japanese Participants With Advanced Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-03-23","conditions":["Neoplasm"],"enrollment":25,"completionDate":"2020-01-14"},{"nctId":"NCT03283696","phase":"PHASE1","title":"A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-10-18","conditions":["Soft Tissue Sarcoma"],"enrollment":24,"completionDate":"2019-08-25"},{"nctId":"NCT03698227","phase":"PHASE2","title":"OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients","status":"TERMINATED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2018-11-12","conditions":["Advanced Soft Tissue Sarcoma"],"enrollment":2,"completionDate":"2020-06-25"},{"nctId":"NCT02677116","phase":"PHASE1","title":"A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-08-29","conditions":["Neoplasm Metastasis"],"enrollment":68,"completionDate":"2019-04-03"},{"nctId":"NCT02326025","phase":"PHASE1","title":"A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-01-22","conditions":["Sarcoma, Soft Tissue"],"enrollment":49,"completionDate":"2018-11-02"},{"nctId":"NCT00913835","phase":"PHASE2","title":"A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-06","conditions":["Ovarian Neoplasms"],"enrollment":125,"completionDate":"2014-02"},{"nctId":"NCT01204710","phase":"PHASE2","title":"A Study of Olaratumab (IMC-3G3) in Prostate Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":["Prostate Cancer"],"enrollment":123,"completionDate":"2013-10"},{"nctId":"NCT02783599","phase":"PHASE1","title":"A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-10-11","conditions":["Soft Tissue Sarcoma"],"enrollment":51,"completionDate":"2018-07-05"},{"nctId":"NCT03437070","phase":"PHASE1","title":"Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2019-06","conditions":["Leiomyosarcoma"],"enrollment":0,"completionDate":"2023-06"},{"nctId":"NCT00918203","phase":"PHASE2","title":"A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-01","conditions":["Non-Small Cell Lung Cancer"],"enrollment":137,"completionDate":"2017-11-17"},{"nctId":"NCT00895180","phase":"PHASE2","title":"Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-07","conditions":["Adult Glioblastoma Multiforme"],"enrollment":80,"completionDate":"2014-03-04"},{"nctId":"NCT01185964","phase":"PHASE1,PHASE2","title":"A Study of Olaratumab in Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":["Sarcoma, Soft Tissue"],"enrollment":148,"completionDate":"2016-04"},{"nctId":"NCT01199822","phase":"PHASE1","title":"Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-09","conditions":["Malignancy","Metastasis"],"enrollment":16,"completionDate":"2012-01"},{"nctId":"NCT01316263","phase":"PHASE2","title":"A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2011-08","conditions":["Gastrointestinal Stromal Tumor (GIST)"],"enrollment":21,"completionDate":"2012-11"},{"nctId":"NCT00768391","phase":"PHASE1","title":"Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-12","conditions":["Solid Tumors"],"enrollment":20,"completionDate":"2010-01"}],"_emaApprovals":[{"date":"2016-11-09","status":"Authorised","company":"Eli Lilly Nederland B.V."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"244924","NDDF":"017019","UNII":"TT6HN20MVF","VANDF":"4036148","INN_ID":"9308","RXNORM":"1855735","UMLSCUI":"C2698152","chemblId":"CHEMBL1743049","ChEMBL_ID":"CHEMBL1743049","KEGG_DRUG":"D09939","DRUGBANK_ID":"DB06043","SNOMEDCT_US":"723523007","IUPHAR_LIGAND_ID":"9172","MESH_SUPPLEMENTAL_RECORD_UI":"C000589393"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2016-","companyName":"Eli Lilly","relationship":"Original Developer"},{"period":"2016","companyName":"Eli Lilly","relationship":"EMA Licensee"}],"publicationCount":115,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01FX10","allCodes":["L01FX10"]},"biosimilarFilings":[],"originalDeveloper":"Eli Lilly And Co","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Eli Lilly","companyId":"eli-lilly","modality":"Monoclonal antibody","firstApprovalDate":"2016","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-10-19T00:00:00.000Z","mah":"ELI LILLY AND CO","brand_name_local":null,"application_number":""},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2016-10-19T00:00:00.000Z","mah":"ELI LILLY AND CO","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2016-10-19T00:00:00.000Z","mah":"ELI LILLY AND CO","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2016-10-19T00:00:00.000Z","mah":"ELI LILLY AND CO","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2016-10-19T00:00:00.000Z","mah":"ELI LILLY AND CO","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2016-10-19T00:00:00.000Z","mah":"ELI LILLY AND CO","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:44:09.576575+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}